Literature Review

Can exercise prevent cognitive decline in patients with early Parkinson’s disease?


 

FROM NEUROLOGY

‘The next blockbuster drug’

Commenting on the study in an interview, Bastiaan R. Bloem, MD, PhD, director of the center of expertise for Parkinson & movement disorders, Radboud University Medical Center, Nijmegen, Netherlands, said exercise might be seen as “the next blockbuster drug.”

Dr. Bloem, who was not involved in the study, noted there is “quite robust evidence now that exercise acts as symptomatic therapy, like a drug, alleviating sleep [disturbances], depression, constipation, and motor symptoms.”

The study “sheds new light on the idea of exercise as not only alleviating symptoms but actually as a potential disease modifier,” said Dr. Bloem, whose research has focused on the beneficial effects of a rigorous exercise program, combined with tablet-based gamificaton and a reward system in stabilizing motor symptoms in patients with Parkinson’s disease over time.

“The reward system created additional motivation for the patients with Parkinson’s disease who often experience depression and apathy that interfere with motivation,” he said.

The current study has important take-home messages for practicing clinicians. “Physicians should encourage exercise in patients, and patients should also take the lead themselves,” Dr. Bloem said. “It doesn’t matter what type of exercise you do, but it should have an aerobic component, should be safe so the patient doesn’t fall down, should have enough intensity to cause the patient to pant, and should be individualized and enjoyable so the patients stick to it,” he emphasized.

Dr. Bloem noted that yoga and mindfulness are also helpful. “If we’ve learned anything from the COVID-19 crisis, it’s that chronic stress is deleterious to all of us and particularly bad for people with PD, because you need dopamine to be able to handle stress, and the lack of dopamine in people with PD makes them deteriorate faster.”

The study was supported by a research grant of National Research Foundation by the Ministry of Science and ICT (MSIT) in Korea. The authors and Dr. Bloem have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Prodrug infusion beats oral Parkinson’s disease therapy for motor symptoms
MDedge Neurology
A skin test for Parkinson’s disease diagnosis?
MDedge Neurology
Sublingual apomorphine alleviates off episodes in Parkinson’s disease
MDedge Neurology
Concussion linked to risk for dementia, Parkinson’s disease, and ADHD
MDedge Neurology
Blood vessels in the eye may diagnose Parkinson’s disease
MDedge Neurology
Ultrasound ablation for Parkinson’s disease: Benefit limited by adverse effects
MDedge Neurology
Prostate drugs tied to lower risk for Parkinson’s disease
MDedge Neurology
Neurologic disorders ubiquitous and rising in the U.S.
MDedge Neurology
Neurologic drug prices jump 50% in five years
MDedge Neurology
Type 2 diabetes linked to increased risk for Parkinson’s
MDedge Neurology